Infinity Pharmaceuticals, Inc. Net Change in Cash
Infinity Pharmaceuticals, Inc. reported Net Change in Cash of -$20.57 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2023-08-10
- Infinity Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$12.58M.
- Infinity Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$27.60M, a 135.31% decline year-over-year.
- Infinity Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was $78.16M, a 850.31% increase year-over-year.
- Infinity Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was $8.22M, a 89.91% increase year-over-year.
- Infinity Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$42.41M, a 181.60% decline from fiscal 2021.
- Infinity Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $51.98M, a 720.72% increase from fiscal 2020.
- Infinity Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was $6.33M.
- Infinity Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was -$26.04M, a 285.89% decline from fiscal 2018.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$20.57M 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | -$12.58M 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | -$42.41M 10-K · filed 2023-03-28 | |||
| 2022-09-30 | -$33.54M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$34.89M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$27.60M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $51.98M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $61.34M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $68.67M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $78.16M 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | $6.33M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | -$3.73M 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $6.66M 10-Q · filed 2021-07-27 | |||
| 2020-03-31 | $8.22M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$26.04M 10-K · filed 2021-03-16 | |||
| 2019-09-30 | -$26.71M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$5.68M 10-Q · filed 2020-07-30 | |||
| 2019-03-31 | $4.33M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $14.01M 10-K · filed 2020-03-03 | |||
| 2018-09-30 | -$2.39M 10-Q · filed 2019-10-30 | |||
| 2018-06-30 | $14.56M 10-Q · filed 2019-07-30 | |||
| 2018-03-31 | -$4.03M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | -$41.13M 10-K · filed 2019-03-14 | |||
| 2017-09-30 | -$42.16M 10-Q · filed 2018-11-05 | |||
| 2017-06-30 | -$9.03M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | $717.00K 10-Q · filed 2018-05-08 |